Render Target: SSR
Render Timestamp:
4/7/2025, 12:51:54 AM EDT
4/7/2025, 4:51:54 AM UTC
Commit: c91f970ca8df4f527662a05c7bd6e4d03c6fa173
XML generation date: 2025-03-07 13:12:41.228
Product last modified at: 2024-05-30T07:01:41.890Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Growth Factors and Cytokines
PDP - Template ID: *******9ad1159

Mouse Insulin-like Growth Factor I (mIGF-I) #9897

We recommend the following alternatives

Inquiry Info. # 9897

Please see our recommended alternatives.

    Product Information

    Formulation

    With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg mIGF-I. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl.

    Storage

    Stable in lyophilized state at -20°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles. Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

    Product Description

    MW (kDa) 7
    Purity >98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mIGF-I. All lots are greater than 98% pure.
    Endotoxin Less than 0.01 ng endotoxin/1 μg mIGF-I.
    Activity The bioactivity of recombinant mIGF-I was determined in a cell proliferation assay using primary human dermal fibroblasts. The ED50 of each lot is between 3-15 ng/ml.
    Molecular Formula Recombinant mIGF-I has a Met on the amino terminus and has a calculated MW of 7,808. DTT-reduced and non-reduced protein migrate as 6 kDa polypeptides. The expected amino-terminal MGPET of recombinant mIGF-I was verified by amino acid sequencing.

    Source / Purification

    Recombinant mouse IGF-I (mIGF-I) Gly33-Ala102 (Accession #NP_001104746) was produced in E. coli at Cell Signaling Technology.

    Background

    Most circulating endocrine-acting IGF-I is produced by hepatocytes, and paracrine- or autocrine-acting IGF-I is produced by defined cell types within specific tissues (1,2). Many neoplastic cells produce IGF-I, which regulates a number of cellular processes including energy metabolism, proliferation, and cell survival (3,4). IGF-I activity is regulated by one or more of the six extracellular IGF-binding proteins (IGFBPs). IGFBPs bind to IGF-I, and most inhibit the binding between IGF-I and the IGF-I receptor (IGFIR) (1,2). Some IGFBPs may increase cell responses to IGF-I. Binding of IGF-I to IGFIR activates the Akt, JNK, and Erk pathways (2). IGF-I and IGFIR are frequently expressed by cancer cells and may contribute to the proliferation and viability of a number of cancer types (1,2).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    PathScan is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.